ChemSpider 2D Image | acalabrutinib | C26H23N7O2

acalabrutinib

  • Molecular FormulaC26H23N7O2
  • Average mass465.507 Da
  • Monoisotopic mass465.191315 Da
  • ChemSpider ID36764951
  • defined stereocentres - 1 of 1 defined stereocentres


More details:






Validated by Experts, Validated by Users, Non-Validated, Removed by Users

1420477-60-6 [RN]
23327568 [Beilstein]
4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide
4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamid [German] [ACD/IUPAC Name]
4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide [ACD/IUPAC Name]
4-{8-Amino-3-[(2S)-1-(2-butynoyl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl}-N-(2-pyridinyl)benzamide [French] [ACD/IUPAC Name]
4-{8-amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl}-N-(pyridin-2-yl)benzamide
acalabrutinib [French] [INN]
acalabrutinib [Spanish] [INN]
More...

Validated by Experts, Validated by Users, Non-Validated, Removed by Users

ACP-196 [DBID]
  • Miscellaneous
    • Chemical Class:

      A member of the class of imidazopyrazines that is imidazo[1,5-a]pyrazine substituted by 4-(pyridin-2-ylcarbamoyl)phenyl, (2S)-1-(but-2-ynoyl)pyrrolidin-2-yl, and amino groups at positions 1, 3 and 8, respectively. It is an irreversible second-generation Bruton's tyrosine kinase (BTK) inhibitor that is approved by the FDA for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. ChEBI CHEBI:167707
    • Bio Activity:

      Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK (Bruton's tyrosine kinase) that has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases, such as EGFR,TEC, and ITK.;Target: BTKAcalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors. Acalabrutinib shows dose dependent inhibition of B-cell receptor signaling in primary CLL cells. In kinase-inhibition assays, acalabrutinib was a more selective BTK inhibitor than ibrutinib. These biochemical findings are physiologically relevant, because acalabrutinib did not;Inhibit EGFR, TEC, or ITK signaling. The findings provide structural, biochemical, and in vitro differentiation of acalabrutinib from ibrutinib. These data, combined with objective clinical responses MedChem Express HY-17600
      Btk MedChem Express HY-17600
      Protein Tyrosine Kinase/RTK; MedChem Express HY-17600

Predicted data is generated using the ACD/Labs Percepta Platform - PhysChem Module, version: 14.00

Density: 1.4±0.1 g/cm3
Boiling Point:
Vapour Pressure:
Enthalpy of Vaporization:
Flash Point:
Index of Refraction: 1.715
Molar Refractivity: 133.2±0.5 cm3
#H bond acceptors: 9
#H bond donors: 3
#Freely Rotating Bonds: 5
#Rule of 5 Violations: 0
ACD/LogP: 0.77
ACD/LogD (pH 5.5): 0.76
ACD/BCF (pH 5.5): 1.86
ACD/KOC (pH 5.5): 43.94
ACD/LogD (pH 7.4): 1.08
ACD/BCF (pH 7.4): 3.85
ACD/KOC (pH 7.4): 90.95
Polar Surface Area: 119 Å2
Polarizability: 52.8±0.5 10-24cm3
Surface Tension: 59.8±7.0 dyne/cm
Molar Volume: 339.0±7.0 cm3

Click to predict properties on the Chemicalize site






Advertisement